Alopecia Areata after COVID-19 Vaccines.

Alopecia areata COVID-19 Hair Hair loss Vaccine

Journal

Skin appendage disorders
ISSN: 2296-9195
Titre abrégé: Skin Appendage Disord
Pays: Switzerland
ID NLM: 101670617

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 07 08 2022
accepted: 13 12 2022
entrez: 17 3 2023
pubmed: 18 3 2023
medline: 18 3 2023
Statut: ppublish

Résumé

Alopecia areata (AA) is a common autoimmune disease characterized by non-scarring hair loss. New onsets of AA have been associated with coronavirus disease 2019 (COVID-19). Various skin diseases have already been reported because of the vaccines (the Pfizer-BioNTech COVID-19 vaccine, the Moderna COVID-19 vaccine, the AstraZeneca vaccine) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report 5 cases of AA after COVID-19 vaccination. The trend shown by patients in this study is an initial worsening after the first dose of the vaccine with the stability of the disease even with subsequent doses. However, it is worth highlighting the case reported by one of our patients who suffered a "booster effect" of the disease with progressive and worsening alopecia with each vaccine booster. The possible mechanism of action lies in the ability of COVID-19 vaccines to induce spike protein, which can lead to molecular mimicry phenomena. In an organism predisposed to autoimmunity, the mRNA vaccine acts as a trigger. Furthermore, we would like to point out how even cytokine storm and simple oxidative stress from SARS-CoV-2 infection can induce not only AA but also other types of hair loss such as telogen effluvium. Thus, this highlights how complex and multifaceted the phenomenon is.

Identifiants

pubmed: 36926281
doi: 10.1159/000528719
pii: sad-0009-0141
pmc: PMC9892995
doi:

Types de publication

Case Reports

Langues

eng

Pagination

141-143

Informations de copyright

Copyright © 2023 by S. Karger AG, Basel.

Déclaration de conflit d'intérêts

None of the contributing authors has any conflict of interest, including specific financial interests or relationships and affiliation relevant to the subject matter or discussed materials in the manuscript.

Références

J Cosmet Dermatol. 2022 May;21(5):1796-1798
pubmed: 35182005
JAAD Case Rep. 2022 Jul;25:25-26
pubmed: 35571458
Clin Exp Vaccine Res. 2022 Jan;11(1):129-132
pubmed: 35223675
Int J Dermatol. 2022 May;61(5):634-635
pubmed: 35107173
JAAD Case Rep. 2022 Feb;20:1-5
pubmed: 34931171
Dermatol Ther. 2022 Jun;35(6):e15433
pubmed: 35266262
Dermatol Clin. 2021 Oct;39(4):653-673
pubmed: 34556254
J Am Acad Dermatol. 2018 Jan;78(1):1-12
pubmed: 29241771
J Cosmet Dermatol. 2021 Dec;20(12):3753-3757
pubmed: 34741583
Pediatr Dermatol. 2016 May;33(3):e218-9
pubmed: 27071855
J Cosmet Dermatol. 2021 Dec;20(12):3727-3729
pubmed: 34559937

Auteurs

Lucia Genco (L)

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Mariateresa Cantelli (M)

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Matteo Noto (M)

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Teresa Battista (T)

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Angela Patrì (A)

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Gabriella Fabbrocini (G)

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Maria Vastarella (M)

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Classifications MeSH